Literature DB >> 29985753

Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells.

Ryutaro Asano1, Yuri Kuroki1, Sachiko Honma2, Mihoko Akabane2, Shunsuke Watanabe2, Shinzo Mayuzumi3, Shuichi Hiyamuta3, Izumi Kumagai1, Koji Sode1,4.   

Abstract

Small bispecific antibodies (bsAbs) are important therapeutic molecules and represent the first bsAb format approved by the United States Food and Drug Administration. Diabody (Db), a small bsAb format, has four possible domain orders; we previously reported the differences in the expression levels and cancer growth inhibition effects upon rearranging the domain order of this format. However, there have been no comprehensive reports on domain rearrangements of bispecific single-chain Db (scDb) and tandem single-chain Fv (taFv), which are widely used bsAb formats. In this study, we designed all possible domain orders for scDb and taFv (each with eight variants) with identical Fv pairs and individually expressed all 16 variants using Escherichia coli, Pichia pastoris, and Brevibacillus choshinensis. Comprehensive investigations showed that the intrinsic functions of the variants were similar to each other, regardless of the expression host system, but expression levels varied depending on the format as well as on the host cell. Among the 16 variants, we found a promising candidate that exhibited high activity and productivity. Furthermore, we determined that B. choshinensis is an attractive expression host because of its secretory production of recombinant proteins.

Entities:  

Keywords:  Brevibacillus choshinensis; CD3; Pichia pastoris; cancer immunotherapy; diabody; effective domain order; epidermal growth factor receptor; host cell; small bispecific antibody; tandem scFv

Mesh:

Substances:

Year:  2018        PMID: 29985753      PMCID: PMC6152445          DOI: 10.1080/19420862.2018.1476815

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  39 in total

Review 1.  Bispecific and bifunctional single chain recombinant antibodies.

Authors:  J Kriangkum; B Xu; L P Nagata; R E Fulton; M R Suresh
Journal:  Biomol Eng       Date:  2001-09

2.  Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Yukiko Sone; Hiroko Kawaguchi; Shintaro Taki; Hiroki Hayashi; Takeshi Nakanishi; Mitsuo Umetsu; Yu Katayose; Michiaki Unno; Toshio Kudo; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

3.  Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.

Authors:  S Saijyo; T Kudo; M Suzuki; Y Katayose; M Shinoda; T Muto; K Fukuhara; T Suzuki; S Matsuno
Journal:  Tohoku J Exp Med       Date:  1995-09       Impact factor: 1.848

4.  Efficient extracellular expression of Bacillus deramificans pullulanase in Brevibacillus choshinensis.

Authors:  Chun Zou; Xuguo Duan; Jing Wu
Journal:  J Ind Microbiol Biotechnol       Date:  2015-12-26       Impact factor: 3.346

5.  Bispecific monoclonal antibodies from hybrid hybridomas.

Authors:  M R Suresh; A C Cuello; C Milstein
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

6.  Brevibacillus expression system: host-vector system for efficient production of secretory proteins.

Authors:  Makoto Mizukami; Hiroshi Hanagata; Akira Miyauchi
Journal:  Curr Pharm Biotechnol       Date:  2010-04       Impact factor: 2.837

7.  Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs.

Authors:  K Els Conrath; M Lauwereys; L Wyns; S Muyldermans
Journal:  J Biol Chem       Date:  2000-10-25       Impact factor: 5.157

8.  The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.

Authors:  Dan Lu; Xenia Jimenez; Larry Witte; Zhenping Zhu
Journal:  Biochem Biophys Res Commun       Date:  2004-05-28       Impact factor: 3.575

9.  Expression of an endotoxin-free S-layer/allergen fusion protein in gram-positive Bacillus subtilis 1012 for the potential application as vaccines for immunotherapy of atopic allergy.

Authors:  Nicola Ilk; Christian-Thomas Schumi; Barbara Bohle; Eva Maria Egelseer; Uwe B Sleytr
Journal:  Microb Cell Fact       Date:  2011-02-10       Impact factor: 5.328

10.  Antibodies to watch in 2018.

Authors:  Hélène Kaplon; Janice M Reichert
Journal:  MAbs       Date:  2018-01-16       Impact factor: 5.857

View more
  4 in total

1.  Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.

Authors:  Koki Makabe; Takeshi Yokoyama; Shiro Uehara; Tomomi Uchikubo-Kamo; Mikako Shirouzu; Kouki Kimura; Kouhei Tsumoto; Ryutaro Asano; Yoshikazu Tanaka; Izumi Kumagai
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

2.  Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation.

Authors:  Atsushi Kuwahara; Keisuke Nagai; Takeshi Nakanishi; Izumi Kumagai; Ryutaro Asano
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

3.  Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats.

Authors:  Ryutaro Asano; Katsuhiro Hosokawa; Shintaro Taki; Shota Konno; Ippei Shimomura; Hiromi Ogata; Mai Okada; Kyoko Arai; Masayoshi Onitsuka; Takeshi Omasa; Takeshi Nakanishi; Mitsuo Umetsu; Izumi Kumagai
Journal:  Sci Rep       Date:  2020-03-18       Impact factor: 4.379

Review 4.  Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.

Authors:  Hyunbo Shim
Journal:  Biomolecules       Date:  2020-02-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.